Dr. Kudo Discusses TACE Plus Sorafenib in HCC

Masatoshi Kudo, MD, PhD
Published: Wednesday, Feb 14, 2018



Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kindai University, discusses the randomized phase II trial comparing transarterial chemoradiation (TACE) plus sorafenib (Nexavar) with TACE alone in patients with hepatocellular carcinoma (HCC).

A total of 156 patients participated in this trial. Median PFS reached 13.5 months with TACE and 25.2 months with TACE plus sorafenib, translating into a 41% reduction in the risk of progression with the addition of the targeted therapy (HR, 0.59, 95% CI 0.41, 0.87; P = .006). The overall survival data are not yet mature since only 74% of the targeted number of events have been observed.

According to Kudo, RECIST is measured for systemic therapy. In clinical practice, TACE was given to patients, and if new lesions formed in a different site, TACE was continued. The new lesion is not progressive disease, it is a natural biology of HCC, explains Kudo. For the TACE combination trial, the RECIST criteria is not a good measurement.
 


Masatoshi Kudo, MD, PhD, Department of Gastroenterology and Hepatology, Kindai University, discusses the randomized phase II trial comparing transarterial chemoradiation (TACE) plus sorafenib (Nexavar) with TACE alone in patients with hepatocellular carcinoma (HCC).

A total of 156 patients participated in this trial. Median PFS reached 13.5 months with TACE and 25.2 months with TACE plus sorafenib, translating into a 41% reduction in the risk of progression with the addition of the targeted therapy (HR, 0.59, 95% CI 0.41, 0.87; P = .006). The overall survival data are not yet mature since only 74% of the targeted number of events have been observed.

According to Kudo, RECIST is measured for systemic therapy. In clinical practice, TACE was given to patients, and if new lesions formed in a different site, TACE was continued. The new lesion is not progressive disease, it is a natural biology of HCC, explains Kudo. For the TACE combination trial, the RECIST criteria is not a good measurement.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x